Islam MR, Gartoulla P, BellRJ, Fradkin P, Davis SR. Prevalence of menopausal symptoms in Asian midlife women: A systematic review. Climacteric 2015 Apr;18(2):157-76.
Islam R, Davis SR, Bell RJ. Bangladesh Midlife Women's Health Study (BMWHS): Methods, Challenges and Experiences. Maturitas 2015 Jan;80(1):89-94.
Worsley R, Jane F, Robinson PJ, Bell RJ, Davis SR. Metformin for overweight women at midlife: a double-blind, randomized, controlled trial. Climacteric 2014 2015 Apr;18(2):270-7.
Fooladi E, Reuter SE, Bell RJ, Robinson PJ, Davis SR. Pharmacokinetics of a Transdermal Testosterone Cream in Healthy Postmenopausal Women Menopause. 2015 Jan;22(1):44-9.
Robinson PJ, Bell RJ, Zecena Morales C, Fradkin P, Davis SR. Minimal trauma fracture in women with breast cancer surviving for at least 5 years from diagnosis. Osteoporos Int. 2015 Feb;26(2):795-800.
Zeleke BM, Davis SR, Fradkin P, Bell RJ. Vasomotor symptoms and urogenital atrophy in older women: a systematic review. Climacteric. 2015 Apr;18(2):112-20.
Gartoulla P, Bell RJ, Worsley R, Davis SR Use of complementary and alternative medicines, for vasomotor and other menopausal symptoms in Australian women aged 40-65 years MJA 2015 Aug 3;203(3):146-153.
Gartoulla P, Worsley R, Bell RJ, Davis SR. Moderate-severe vasomotor and sexual symptoms remain problematic for 60-65 year old women. Menopause 2015 Aug;81(4):487-92
Davis SR, Tan AGC & Bell RJ. Targeted assessment of fracture risk in women at midlife. Osteoporosis International, 2016 vol 26, no. 6, pp. 1705-1712.
Robinson PJ, Bell RJ, Morales CSZ, Fradkin P & Davis SR. 2015. Minimal-trauma fracture in women with breast cancer surviving for at least 5 years from diagnosis. Osteoporosis International, 2015vol 26, no. 2, pp. 795-800.
Gartoulla P, Bell RJ, Worsley R & Davis SR. Moderate-severely bothersome vasomotor symptoms are associated with lowered psychological general wellbeing in women at midlife. Maturitas, 2015 vol 81, no. 4, pp. 487-492.
Zeleke BM, Davis SR, Fradkin P & Bell RJ. Vasomotor symptoms and urogenital atrophy in older women: a systematic review. Climacteric, vol 18, no. 2, pp. 112-120.
Toppi J, Fairley J, Cicuttini FM, Cook JL, Davis SR, Bell RJ, Hanna F & Wang Y. 2015. Factors associated with magnetic resonance imaging defined patellar tendinopathy in community-based middle-aged women: a prospective cohort study. BMC Musculoskeletal Disorders, vol 16, no. 1 (Art. No: 184), pp. 1-7.
Islam MR, Bell RJ, Billah MB, Hossain MB & Davis SR. 2015. Lack of understanding of cervical cancer and screening is the leading barrier to screening uptake in women at midlife in Bangladesh: population-based cross-sectional survey. Oncologist, vol 20, no. 12, pp. 1386-1392.
Zeleke BM, Davis SR, Fradkin p, Bell RJ. Vasomotor symptoms and urogenital atrophy in older women: a systematic review. Climacteric. 2015 Apr;18(2):112-20.
Davis SR, Baber R. Reproductive endocrinology: Menopausal hormone therapy-ovarian cancer risk revisited. Nat Rev Endocrinol 2015 Jun;11(6):322-3.
Davis SR, Parish SJ. Testosterone in women: can the challengers be met? Lancet Diabetes Endocrinol 2015 Aug;3(8):588-90.
Davis, SR & Wahlin-Jacobsen, S. 2015. Testosterone in women – the clinical significance. The Lancet Diabetes & Endocrinology, vol 3, no. 12, pp. 980-992.
Stuenkel CA, Davis SR, Gompel A, Lumsden MA, Murad MH, Pinkerton JAV & Santen RJ. Treatment of symptoms of the menopause: An endocrine society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism, 2015 vol 100, no. 11, pp. 3975-4011.
Davis SR & Parish SJ. 2015. Testosterone in women: Can the challenges be met? The Lancet Diabetes & Endocrinology, vol 3, no. 8, pp. 588-590. DOI: 10.1016/S2213-8587(15)00207-7.
Davis SR & Baber R. 2015. Reproductive endocrinology: Menopausal hormone therapy-ovarian cancer risk revisited. Nature Reviews Endocrinology, vol 11, no. 6, pp. 322.
Davis SR. 2015. Androgen therapy for postmenopausal women. N Panay, P Briggs & G Kovacs (eds), Managing the Menopause: 21st Century Solutions. Cambridge University Press, Cambridge UK, pp. 136-141.
Davis SR, Wahlin-Jacobsen S. 2015. Testosterone in women – the clinical significance. Lancet Diabetes Endocrinol, 2015 Dec;3(12):980-92.
Davis SR, Lambrinoudaki I, et al. 2015. Menopause. Nat Rev Dis Primers. 2015 Apr 23;1:15004.
Letter to the Editor
Hussain SM, Cicuttini FM, Bell RJ, Robinson PJ, Davis SR, Giles GG, Graves S, Milne RL & Wang Y. 2015. 'Reply' Arthritis & Rheumatology, vol 67, no. 1, pp. 315-316.
Davis SR & Bell RJ. 2015. Letter to the editor: Randolph J, et al. Masturbation frequency and sexual function domains are associated with serum reproductive hormone levels across the menopausal transition. Journal of Clinical Endocrinology and Metabolism, vol 100, no. 2.
Davis SR, Baber R, 2015, 'Menopausal hormone therapy–ovarian cancer risk revisited' Nat Rev Endocrinol. 2015 Jun;11(6):322-3.